NF-κB contributes to Smac mimetic-conferred protection from tunicamycin-induced apoptosis.


Journal

Apoptosis : an international journal on programmed cell death
ISSN: 1573-675X
Titre abrégé: Apoptosis
Pays: Netherlands
ID NLM: 9712129

Informations de publication

Date de publication:
04 2019
Historique:
pubmed: 27 1 2019
medline: 4 4 2020
entrez: 26 1 2019
Statut: ppublish

Résumé

Smac mimetics that deplete cellular inhibitor of apoptosis (cIAP) proteins have been shown to activate Nuclear Factor-kappa B (NF-κB). Here, we report that Smac mimetic-mediated activation of NF-κB contributes to the rescue of cancer cells from tunicamycin (TM)-triggered apoptosis. The prototypic Smac mimetic BV6 activates non-canonical and canonical NF-κB pathways, while TM has little effect on NF-κB signaling. Importantly, ectopic expression of dominant-negative IκBα superrepressor (IκBα-SR), which inhibits canonical and non-canonical NF-κB activation, significantly reversed this BV6-imposed protection against TM. Similarly, transient or stable knockdown of NF-κB-inducing kinase, which accumulated upon exposure to BV6 alone and in combination with TM, significantly counteracted BV6-mediated inhibition of TM-induced apoptosis. Interestingly, while cIAP2 was initially degraded upon BV6 treatment, it was subsequently upregulated in an NF-κB-dependent manner, as this restoration of cIAP2 expression was abolished in IκBα-SR-overexpressing cells. Interestingly, upon exposure to TM/BV6 apoptosis was significantly increased in cIAP2 knockdown cells. Furthermore, NF-κB inhibition partially prevented BV6-stimulated expression of Mcl-1 upon TM treatment. Consistently, Mcl-1 silencing significantly inhibited BV6-mediated protection from TM-induced apoptosis. Thus, NF-κB activation by Smac mimetic contributes to Smac mimetic-mediated protection against TM-induced apoptosis.

Identifiants

pubmed: 30680482
doi: 10.1007/s10495-018-1507-2
pii: 10.1007/s10495-018-1507-2
doi:

Substances chimiques

Apoptosis Regulatory Proteins 0
DIABLO protein, human 0
Inhibitor of Apoptosis Proteins 0
Intracellular Signaling Peptides and Proteins 0
Mitochondrial Proteins 0
Myeloid Cell Leukemia Sequence 1 Protein 0
NF-kappa B 0
Tunicamycin 11089-65-9
NF-KappaB Inhibitor alpha 139874-52-5

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

269-277

Subventions

Organisme : Interuniversity Attraction Poles Program, Belgian State, Science Policy Office
ID : IUAP/32
Pays : International

Auteurs

Behnaz Ahangarian Abhari (BA)

Institute for Experimental Cancer Research in Pediatrics, Goethe-University, Komturstr. 3a, 60528, Frankfurt, Germany.

Nicole McCarthy (N)

Institute for Experimental Cancer Research in Pediatrics, Goethe-University, Komturstr. 3a, 60528, Frankfurt, Germany.

Patrizia Agostinis (P)

Cell Death Research and Therapy Unit, Department of Cellular and Molecular Medicine, KU Leuven, 3000, Leuven, Belgium.

Simone Fulda (S)

Institute for Experimental Cancer Research in Pediatrics, Goethe-University, Komturstr. 3a, 60528, Frankfurt, Germany. simone.fulda@kgu.de.
German Cancer Consortium (DKTK), Partner Site Frankfurt, Heidelberg, Germany. simone.fulda@kgu.de.
German Cancer Research Center (DKFZ), Heidelberg, Germany. simone.fulda@kgu.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH